Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Enrolling by invitation × Neoplasms × durvalumab × Clear all

Phase

Status

Completed 10 Active not recruiting 5 Recruiting 4 Terminated 2 Unknown 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Small Cell Lung Carcinoma 1 Neoplasms 1

Interventions

Specimen Handling 3 somapacitan 1 ibrutinib 1 gallium 68 PSMA-11 1 exemestane 1 durvalumab 1 Tumor Burden 1 Telemedicine 1 Tamoxifen 1 Semen Analysis 1 Radiography, Panoramic 1 Protons 1 Physical Examination 1 Photons 1 Myofascial Release Therapy 1 Letrozole 1 JNJ-64619178 1 JNJ-64264681 1 High-Intensity Interval Training 1 Exercise 1 Electrocardiography 1 Educational Status 1 Community Health Workers 1 Blood Specimen Collection 1 Angptl4 protein, mouse 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05303532 2026-02-23

ROSY-D

AstraZeneca

Phase 3 Enrolling by invitation

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡